Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of oncology company Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA ) plummeted 17% today after the U.S. Food and Drug Administration said that it's investigating its leukemia drug Iclusig.
So what: The stock plunged a whopping 66% on Wednesday after the FDA halted all new trials of Iclusig due to safety concerns, and today's announcement only raises more uncertainty among investors over the drug going forward. Specifically, the FDA is looking into the increasing number of reports of serious and life-threatening blood clots and severe narrowing of blood vessels in patients, prompting a few analysts to downgrade the stock on the risk of even more bad news ahead.
Now what: The FDA is urging doctors and patients to report side effects involving Iclusig.
"Data from clinical trials and postmarket adverse event reports show that serious adverse events have occurred in patients treated with Iclusig, including heart attacks resulting in death, worsening coronary artery disease, stroke, narrowing of large arteries of the brain, severe narrowing of blood vessels in the extremities, and the need for urgent surgical procedures to restore blood flow," the FDA said in a statement. "The FDA is providing this information to patients and health care professionals while it continues its investigation. We are actively working to further evaluate these adverse events and will notify the public when more information is available."
So while biotech-savvy investors might want to take a deeper look at this issue and Ariad's assets, average Fools would probably do well to maintain their distance.
More reliable ways to build wealth
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.